Overview

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Aprepitant
Cyclophosphamide
Fosaprepitant